Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
469 GBX | +3.17% | +5.82% | -3.70% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Apr. 19 | Peel Hunt starts NatWest and Barclays at 'buy' | AN |
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.8 for the current period. Therefore, the company is undervalued.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Employment Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.70% | 1.84B | B- | ||
+8.71% | 3.37B | B- | ||
-8.33% | 1.99B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MPI Stock
- Ratings PageGroup plc